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Methods: A model of HBV is described by: x, y, v, z
which represent uninfected cells, infected cells, free virus,
and CTL cells respectively. Here the infected cells were
divided into two parts with one part having drug resistance
and the other part having none. The model includes
11 parameters: l, d, b, a, p, k1, k2, u, c, b, t. During
treatment of AD, we chose {l, d, b, a, p, k1, k2, u, c, b,
t} = {4.621e5, 6.9e-3, 7.08e-11, 6.9e-3, 1.5e-9, 1, 0.93,
0.08, 0.35, 2.251e-2, 10.6}. During treatment of ETV, we
choose {k2, u, t} = {0.99, 0.18, 1.6{ with other parameters
unchanged. Here the change of the three parameters can
imply the difference of therapy effect of AD and ETV.
Results: The simulation data of our model are qualitatively
agreement with the clinical ones, especially the HBV DNA
decrease when switch to ETV treatment.
Conclusion: The results show that our time-delay therapy
model may possibly capture the dynamics of HBV infection
and anti-HBV infection treatment under different drug.
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PP-103 Immune responses elicited in hepatitis B virus
transgenic mice by B7-H1 and HBsAg vaccine
W.J. Su1 *, X.F. Bai1, B. Liu1. 1Tangdu Hospital, The Fourth
Military Medical University, China
Background: The prevalence and infection hepatitis B virus
is a serious problem in the world. Recent studies showed
that the PD-1/PD-L pathway contributed directly to T cell
dysfunction and lack of viral control in established chronic
infection. In the present study, we try to improve the
immune effect of HBsAg vaccination in HBV transgenic mice
by blocking PD-1/PD-L pathway in vivo and to seek new
methods for the treatment of chronic hepatitis B.
Methods: Fifteen HBV Tg mice were randomized into
three groups with 5 mice each, and designated as HBsAg
vaccine group, vaccine and B7-H1 group and control
group, respectively. The anti-HBs of the three groups were
detected by ELISA. The splenocytes of the mice were
stimulated with HBsAg (10mg/ml). The concentrations of
IL-2 and IFN-g were detected by ELISA. The number of IFN-g
secreting cells was measured by ELISPOT.
Results: The anti-B7-H1 in serum was detected in the mice
immunized with B7-H1 and the antibody titer increased
with the immune times. There was no difference of anti-
HBs positive rate between HBsAg group and HBsAg+B7-
H1 group at 6th week and 8th week after immunization.
Concentrations of IL-2 and IFN-g were elevated in both
HBsAg group and HBsAg+B7-H1 group than that in control
group (P < 0.05). Moreover, The numbers of HBs-specifc IFN-g
secreting T cells is also increased in both the HBsAg group
and HBsAg+B7-H1 group when compared with the control
group, and the outcomes showed no difference between
the two experimental groups (P > 0.05).
Conclusion: (1) HBsAg vaccine can increase the cellular and
humoral immune response in HBV Tg mice and reconstruct
immune response to HBsAg. (2) B7-H1 vaccine can not
enhance the humoral and cell immune responses in HBV
Tg mice immunized with HBsAg.
PP-104 Analysis of prognostic factors in patients with
HBV-related liver failure and construction of a
prognostic model to predict patient survival
H.-B. Gao1 *, C. Pan1, M.-H. Lin1, J.-K. Fang1, J.-J. Zhang1,
R. Zhou1, W. Zhou1, L.-J. Xu1. 1The Afﬁliated Infectious
Disease Hospital, Fujian Medical University (Fuzhou
Infectious Diseases Hospital), China
Objective: The aim of this study was to analyze variables
that may affect survival of patients with HBV-related
liver failure, identify the independent predictors for
development of a prognostic survival model, and evaluate
its predictive power.
Methods: In this retrospective cohort study, 569 patients
were diagnosed with HBV-related liver failure between
January 2004 and December 2007. Univariate and
multivariate Cox proportional hazards regression analyses
were applied to such variables as age, sex, disease
complications, biochemical markers, coagulation markers,
and HBV DNA loads to identify independent risk factors
for establishment of a prognostic survival model, and 79
conﬁrmed cases of HBV-related liver failure were used to
evaluate the model’s predictive capacity.
Results: Hepatic encephalopathy, pulmonary infection,
upper gastrointestinal bleeding (UGIB), albumin, AST, creati-
nine, international normalized ratio (INR) were determined
to be independent risk factors (P< 0.01); accordingly, the
prognostic index (PI) = 4.98× hepatic encephalopathy +
4.57×pulmonary infection + 4.41× upper gastrointestinal
bleeding 9.69× Ln(Alb[g/L]) + 2.46× Ln(AST[U/L]) +
5.18× Ln(Cr[mmol/L]) + 3.35×Ln(INR) 15.36, which was
able to accurately predict the 90-d survival.
Conclusions: Survival of patients with HBV-related
liver failure can be accurately predicted based on
seven independent predictors: hepatic encephalopathy,
pulmonary infection, upper gastrointestinal bleeding
(UGIB), albumin, AST, creatinine, and INR. Thus, these
factors might be of reference value in the choice of clinical
treatment.
PP-105 miR-338 3p is down-regulated by the wild
and mutant HBx and inhibits proliferation by
targeting CyclinD1
X.Y. Fu1,2 *, D.M. Tan, Z.H. Hou, Z.L. Hu3,4, G.Z. Liu,
Y. Ouyang, F. Liu. 1Department of Infectious Disease,
2Xiangya Hospital, Central South University, 3The Second
hospital of Nanjing, 4Nanjing, Jiangsu, China
Background: Hepatocellular carcinoma (HCC) is one of
the most common malignancies. Numerous studies have
suggested the potentially oncogenic roles of wild or mutant
hepatitis B virus X protein (HBx) in hepatocarcinogenesis.
To date, however, it remains unknown if HBx regulates
the expression of microRNAs (miRNAs) which negatively
regulate gene expression, playing essential roles in cell
differentiation and carcinogenesis.
Methods: MiRNA microarrays were employed to compare
the expression of cellular miRNAs in the LO2 cell line
that have been successfully established transfecting with
recombinant plasmid pcDNA3.0/HBx-d382, pcDNA/HBx and
plasmid pcDNA3.0 previously. Real-time Quantitative PCR
was used to conﬁrm the chip results. MiR-338 3p was
functionally characterized in LO2 cells with transiently
altered miR-338 3p expression. The direct target of miR-
338 3p was validated using 3′UTR-reporter assay.
Results: Compared with the LO2/pcDNA3.0 cell, a total
of 1 miRNAs exhibited higher expression and 5 miRNAs
demonstrated lower expression in the LO2/HBx-d382 cell,
while 4 up-regulated and 11 down-regulated miRNAs were
observed in LO2/HBx cell. MiR-338 3p, which both down-
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regulated by wild and mutant HBx, demonstrated a lower
level in the LO2/HBx-d382 cell. Further characterization of
miR-338 3p revealed that it negatively regulated cellular
proﬁleration. Cell cycle analysis showed that miR-338 3p
induced cell cycle arrest at the G1/S phase. A dual-
luciferase reporter assay demonstrated that the 3′UTR of
CyclinD1 were directly bound to miR-338 3p and western
blotting analysis further indicated that miR-338 3p down-
regulated the expression of CyclinD1.
Conclusion: This study demonstrates that HBx can
inﬂuence cellular miRNA expression. The deregulation of
the expression of miR-338 3p by HBx may represent a
potential novel pathway which HBx acts to deregulate cell
proliferation leading to hepatocarcinogenesis.
PP-106 Relationship between HBsAg, HBcAg expression
and serum HBV DNA level in 140 patients with
chronic hepatitis B
Y. Yan1 *, L. Mai1, G.L. Lin1, J. Liu1, J.Y. Zhu1. 1The Third
Afﬁliated Hospital of Sun Yat-sen University, China
Objective: The aim of this study was to investigate the
relationship between HBsAg, HBcAg expression and serum
HBV DNA level.
Methods: The expression of HBsAg, HBcAg in the livers
of 140 patients with chronic hepatitis B was detected by
immunohistochemistry. And the level of serum hepatitis B
virus DNA (HBV DNA) was tested. Statistical signiﬁcance was
assessed using One-Way analysis of variance (ANOVA).
Results: Serum HBV DNA level in 13 patients with
HBsAg ( ~±), 108 patients with (+~++) and 19 patients
with (+++~++++) was 5.313±1.874 copies log10/ml,
6.010±2.016 copies log10/ml and 5.664±1.548 copies
log10/ml respectively (P= 0.408). Serum HBV DNA level in
42 patients with HBsAg ( ~±), 79 patients with (+~++)
and 19 patients with (+++~++++) was 5.886±1.997 copies
log10/ml, 5.968±2.020 copies log10/ml and 5.634±1.551
copies log10/ml respectively (P= 0.800).
Conclusions: The expression of HBsAg, HBcAg in the liver
does not correlate with serum HBV DNA level.
PP-107 Cause analysis of chronic HBV infected patients
without antiviral therapy in the Pearl River
Delta region
G.L. Lin1 *, X.J. Zhang1, Y. Yan1, Y.K. Wu1, X.Y. Li1,
L.Q. Yang1, Y.T. Chong1. 1The third afﬁliated hospital of
Sun Yat-sen University, China
Objectives: To analyze the causes of the patients with
chronic Hepatitis B without taking antiviral therapy and the
strategies of dealing with it.
Method: We make long-termed observation on the patients
with chronic Hepatitis B Virus (HBV) infection, who were
voluntarily to be followed up in our clinic department, and
analyze statistically the objective and subjective causes of
patient without taking antiviral therapy.
Results: In total eligible 951 cases, 424 cases didn’t
receive the antiviral therapy. 105 out of 424 cases had the
indications of the antiviral therapy (105/424, 24.8%), the
other 319 cases had no indications of the therapy (319/424,
75.2%). The ratio of female (124/202, 61.4%) who didn’t
get the antiviral therapy was signiﬁcant higher than that
of male (300/749, 40.0%). 49 out of 105 cases who had
the indications of the antiviral therapy worried about the
unhealthful effect on their fertility by the antiviral drugs
and put off antiviral therapy (49/105, 46.7%); 31out of
105 cases could not pay for the antiviral therapy (31/105,
29.5%); 19 out of 105 cases queried the safety of the
antiviral drugs and uncertainty of course of the treatment
(19/105, 18.1%). 6 out of 105 cases were because of poor
compliance (6/105, 5.7%).
Conclusions: No antiviral indications was the main cause
of the untreated group. The causes of that patients
with indications didn’t receive antiviral therapy were
that worrying about their fertility, fees of the treatment
hard to bear, querying the safety of the antiviral drugs
and uncertainty of course of the treatment, and poor
compliance. Formal long-termed follow up by the clinicians,
good communications between clinicians and patients and
health education might improve the effects of anti-HBV
treatment.
PP-108 Investigation on serum HBV viral loads and
the changes of liver pathological features in
158 patients with chronic hepatitis B
Y. Yan1 *, L. Mai1, J. Liu1, J.Y. Zhu1, Y. Zhang1. 1The Third
Afﬁliated Hospital of Sun Yat-sen University, China
Objective: To investigate the relationship between serum
HBV DNA loads and liver pathological changes in the patients
with chronic hepatitis B.
Methods: The relationship among HBV DNA loads, live
histological inﬂammation grades and ﬁbrosis stages of
158 cases was analyzed.
Results: The serum HBV DNA loads in HBeAg-positive group
with inﬂammation grades G0 1 (6 patients), G2 (74 patients)
and G3 4 (25 patients) were 5.580±1.098 copies log10/ml,
6.520±2.004 copies log10/ml and 6.950±1.467 copies
log10/ml respectively. There was no signiﬁcant difference
in patients of three inﬂammation grades (P= 0.250). The
serum HBV DNA loads in HBeAg-positive group with liver
tissues ﬁbrosis stages of S0 1 (23 patients), S2 (56 patients),
S3 4 (26 patients) were 6.599±1.832 copies log10/ml,
6.559±2.012 copies log10/ml, 6.562±1.601 copies log10/ml
respectively, the difference was not signiﬁcant (P= 0.996).
The serum HBV DNA loads in HBeAg-negative group with
inﬂammation grades G0 1 (8 patients), G2 (17 patients)
and G3 4 (28 patients) were 2.132±1.875 copies log10/ml,
4.745±2.250 copies log10/ml and 5.581±2.305 copies
log10/ml respectively. The serum HBV DNA level in patients
with G2 and G3 4 inﬂammation grades was signiﬁcant
higher than in patients with G0 1 inﬂammation grades
(P= 0.001). The serum HBV DNA loads in HBeAg-negative
group with liver tissues ﬁbrosis stages of S0 1 (10 patients),
S2 (45 patients), S3 4 (18 patients) were 2.689±3.225 copies
log10/ml, 5.127±1.833 copies log10/ml, 5.375±2.410 copies
log10/ml respectively. The serum HBV DNA level in patients
with ﬁbrosis stages of S2 and S3 4 was signiﬁcant higher than
in patients with ﬁbrosis stages of S0 1 (P = 0.005).
Conclusions: The serum HBV DNA level does not correlate
with the inﬂammation grades and ﬁbrosis stages of liver
tissues in HBeAg-positive patients. The serum HBV DNA
loads display a positive correlation with the inﬂammation
grades and ﬁbrosis stages of liver tissues in HBeAg-negative
patients.
PP-109 Association of IL-6 gene polymorphism and its
levels in HBV related hepatocellular carcinoma
progression in India
R. Saxena1, Y.K. Chawla2, J. Kaur1 *. 1Department of
Biochemistry, Postgraduate Institute of Medical Education
and Research, Chandigarh, 160 012, India, 2Department of
hepatology, Postgraduate Institute of Medical Education
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Objectives: Hepatitis B Virus (HBV) infection is a primary
risk factor for hepatocellular carcinoma (HCC), the ﬁfth
most frequent cancer, worldwide. The present study was
undertaken to analyze the association of IL-6 ( 572) and
